These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8023553)

  • 1. Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens.
    Conley AJ; Conard P; Bondy S; Dolan CA; Hannah J; Leanza WJ; Marburg S; Rivetna M; Rusiecki VK; Sugg EE
    Vaccine; 1994 Apr; 12(5):445-51. PubMed ID: 8023553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.
    Letvin NL; Robinson S; Rohne D; Axthelm MK; Fanton JW; Bilska M; Palker TJ; Liao HX; Haynes BF; Montefiori DC
    J Virol; 2001 May; 75(9):4165-75. PubMed ID: 11287566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.
    Golding B; Inman J; Highet P; Blackburn R; Manischewitz J; Blyveis N; Angus RD; Golding H
    J Virol; 1995 Jun; 69(6):3299-307. PubMed ID: 7745677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclic V3-loop-related HIV-1 conjugate vaccines. Synthesis, conformation and immunological properties.
    Tolman RL; Bednarek MA; Johnson BA; Leanza WJ; Marburg S; Underwood DJ; Emini EA; Conley AJ
    Int J Pept Protein Res; 1993 May; 41(5):455-66. PubMed ID: 8320039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.
    Smith AD; Geisler SC; Chen AA; Resnick DA; Roy BM; Lewi PJ; Arnold E; Arnold GF
    J Virol; 1998 Jan; 72(1):651-9. PubMed ID: 9420270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of HIV vaccine candidate peptides by screening random phage epitope libraries.
    Keller PM; Arnold BA; Shaw AR; Tolman RL; Van Middlesworth F; Bondy S; Rusiecki VK; Koenig S; Zolla-Pazner S; Conard P
    Virology; 1993 Apr; 193(2):709-16. PubMed ID: 7681612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R; Meyer D
    Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.
    Liao HX; Cianciolo GJ; Staats HF; Scearce RM; Lapple DM; Stauffer SH; Thomasch JR; Pizzo SV; Montefiori DC; Hagen M; Eldridge J; Haynes BF
    Vaccine; 2002 May; 20(17-18):2396-403. PubMed ID: 12009296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
    Ching LK; Vlachogiannis G; Bosch KA; Stamatatos L
    J Virol; 2008 Jan; 82(2):949-56. PubMed ID: 18003732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice.
    Boudet F; Keller H; Kieny MP; Thèze J
    Mol Immunol; 1995 May; 32(7):449-57. PubMed ID: 7783749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes.
    Chang JS; Choi MJ; Kim TY; Cho SY; Cheong HS
    Vaccine; 1999 Mar; 17(11-12):1540-8. PubMed ID: 10195791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.
    Rovinski B; Haynes JR; Cao SX; James O; Sia C; Zolla-Pazner S; Matthews TJ; Klein MH
    J Virol; 1992 Jul; 66(7):4003-12. PubMed ID: 1602531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of high levels of epitope-specific antibodies by epitope/peptide candidate vaccines against human immunodeficiency virus type-1 (HIV-1).
    Yu T; Bai Y; Dierich MP; Chen YH
    Microbiol Immunol; 2000; 44(2):105-10. PubMed ID: 10803497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1).
    Laisney IL; Strosberg AD
    Immunol Lett; 1999 Apr; 67(3):185-92. PubMed ID: 10369125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.
    Wagner R; Modrow S; Böltz T; Fliessbach H; Niedrig M; von Brunn A; Wolf H
    Arch Virol; 1992; 127(1-4):139-52. PubMed ID: 1456889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
    J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.
    Zolla-Pazner S; Cohen S; Pinter A; Krachmarov C; Wrin T; Wang S; Lu S
    Virology; 2009 Sep; 392(1):82-93. PubMed ID: 19632700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.